Open AccessClinical Utility of CLIA-Grade AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer
Author(s) -
Mark C. Markowski,
John L. Silberstein,
James R. Eshleman,
Mario A. Eisenberger,
Jun Luo,
Emmanuel S. Antonarakis
Publication year - 2017
Publication title -
jco precision oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.405
H-Index - 22
ISSN - 2473-4284
DOI - 10.1200/po.17.00127
Subject(s) - enzalutamide , taxane , prostate cancer , medicine , docetaxel , oncology , androgen receptor , cabazitaxel , androgen deprivation therapy , cancer , breast cancer
A splice variant of the androgen receptor, AR-V7, confers resistance to AR-targeted therapies (ATTs) but not taxane chemotherapies in patients with metastatic castration-resistant prostate cancer. Since August 2015, a clinical-grade assay to detect AR-V7 messenger RNA expression in circulating tumors cells (CTCs) has been available to providers through a Clinical Laboratory Improvement Amendments-certified laboratory at Johns Hopkins University.